The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production1
Abstract
Recent data suggest an interaction between the renin-angiotensin-aldosterone system and fibrinolysis. Although previous work has focused on the effect of angiotensin II (Ang II) on plasminogen activator inhibitor (PAI-1) expression, the present study tests the hypothesis that aldosterone contributes to the regulation of PAI-1 expression. To test this hypothesis in vitro, luciferase reporter constructs containing the human PAI-1 promoter were transfected into rat aortic smooth muscle cells. Exposure of the cells to 100 nmol/L Ang II resulted in a 3-fold increase in luciferase activity. Neither 1 μmol/L dexamethasone nor 1 μmol/L aldosterone alone increased PAI-1 expression. However, both dexamethasone and aldosterone enhanced the effect of Ang II in a dose-dependent manner. This effect was abolished by mutation in the region of a putative glucocorticoid-responsive element. A similar interactive effect of Ang II and aldosterone was observed in cultured human umbilical vein endothelial cells. The time course of the effect of aldosterone on Ang II-induced PAI-1 expression was consistent with a classical mineralocorticoid receptor mechanism, and the effect of aldosterone on PAI-1 synthesis was attenuated by spironolactone. To determine whether aldosterone affected PAI-1 expression in vivo, we measured local venous PAI-1 antigen concentrations in six patients with primary hyperaldosteronism undergoing selective adrenal vein sampling. PAI-1 antigen, but not tissue plasminogen activator antigen, concentrations were significantly higher in adrenal venous blood than in peripheral venous blood. Taken together, these data support the hypothesis that aldosterone modulates the effect of Ang II on PAI-1 expression in vitro and in vivo in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Chen, Y.-Q., Su, M., Walia, R. R., Hao, Q., Covington, J. W., & Vaughan, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8225 · Cited by 217
Self-citation
Cited by
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
VAUGHAN, D. E. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01420.x · Cited by 507
Self-citationInsulin Resistance and Cardiovascular Disease1
McFarlane, S. I., Banerji, M., & Sowers, J. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7202 · Cited by 501
Zeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
Brown, N. J. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.110 · Cited by 451
Self-citationHenry, B. M., Vikse, J., Benoit, S., Favaloro, E. J., & Lippi, G. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.027 · Cited by 383
Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment
Young, W. F. (2003) · Endocrinology · doi:10.1210/en.2003-0279 · Cited by 376
Rader, D. J. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.003 · Cited by 346
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 320
Self-citationAldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
Mechanisms of progression of chronic kidney disease
Fogo, A. B. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0524-0 · Cited by 263
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
Brown, N. J., Nakamura, S., Ma, L., Nakamura, I., Donnert, E., Freeman, M., Vaughan, D. E., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00277.x · Cited by 255
Self-citationThe Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137
Self-citation
Metadata
- Authors
- Brown, N. J., Kim, K.-S., Chen, Y.-Q., Blevins, L. S., Nadeau, J. H., Meranze, S. G., & Vaughan, D. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-01-01
- Volume
- 85
- Issue
- 1
- Pages
- 336-344
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1979839191
- Cited by
- 182
- References
- 3
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.